Eris has outpaced the Indian Pharmaceutical Market (IPM) growth with a CAGR of 19.7% in Chronic+Subchronic and 13.7% in Acute therapy segment.
Chronic + Subchronic category contributes to 84% of our revenues as compared to 53% contribution to the IPM.
Source : AIOCD MAT Mar 19
CAGR: Compounded annual growth between FY 13 and FY 19
Our field force productivity of INR 4.1 Lac (YPM – Yield per Man per Month) is industry-leading and we are amongst the most productive companies in the Industry.
Our product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists. Super specialists and specialists contribute to 86.3% of our total prescriptions as compared to 62.6% for the IPM.
Super specialist and specialist doctor prescription contribution
Source : SMSRC MAT FEB’19
|SPECIALTY||Rank MAT FEB 19|
Source SMSRC MAT Feb 19, Prescription rank within Eris represented market